Signal Alteration of Substantia Nigra on 3.0T Susceptibility-weighted Imaging in Parkinson’s Disease and Vascular Parkinsonism

Abstract

Recent researches have found that 7 Tesla SWI can detect the alteration of substantia nigra hyperintensity in Parkinson’s disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). The aim of this study was to investigate whether 3 Tesla SWI (3T SWI) can visualize anatomical alterations occurring in a hyperintense structure of the substantia nigra in PD and vascular parkinsonism (VP), and whether the evaluation of abnormal signal can be used as a factor in the differential diagnosis of PD and VP. Using 3 Tesla MRI, we evaluated 38 healthy subjects, 33 patients with PD and 34 patients with VP. Two blinded readers independently assessed the images. We found that the dorsolateral nigral hyperintensity was absent in 31 of 33 patients with PD and 15 of 34 patients with VP. The dorsolateral nigral hyperintensity was present in 19 of 34 patients with VP and 35 of 38 healthy controls. Group comparisons of absence of dorsolateral nigral hyperintensity revealed significant differences between the patients with PD and those with VP (P<0.001). The sensitivity of SWI for PD was 93.9% and the specificity was 92.1%. Visual assessment of dorsolateral nigral hyperintensity on high-field SWI scans may serve as a new simple diagnostic imaging marker for PD. And our study results indicate that 3T SWI can be used as a tool to identify PD and VP.

Keywords

magnetic resonance imaging / susceptibility-weighted imaging / Parkinson’s disease / vascular parkinsonism / substantia nigra

References

[1] DamierP, HirschE, AgidY, et al.. The substantia nigra of the human brain II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain, 1999, 122: 1437-1448 Pt 8

[2] DamierP, HirschEC, AgidY, et al.. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain, 1999, 122: 1421-1436 Pt 8

[3] CosottiniM, FrosiniD, PesaresiI, et al.. MR Imaging of the substantia nigra at 7 T enables diagnosis of Parkinson disease. Radiology, 2014, 271(3): 831-838

[4] NohY, SungYH, LeeJ, et al.. Nigrosome 1 detection at 3T MRI for the diagnosis of early-stage idiopathic Parkinson disease: Assessment of diagnostic accuracy and agreement on imaging asymmetry and clinical laterality. AJNR Am J Neuroradiol, 2015, 36(11): 2010-2016

[5] SchwarzST, AfzalM, MorganPS, et al.. The ‘swallow tail’ appearance of the healthy nigrosome — a new accurate test of Parkinson’s disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One, 2014, 9(4): e93814

[6] CosottiniM, FrosiniD, PesaresiI, et al.. Comparison of 3T and 7T susceptibility-weighted angiography of the substantia nigra in diagnosing Parkinson disease. AJNR Am J Neuroradiol, 2015, 36: 461-466

[7] ReiterE, MuellerC, PinterB, et al.. Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. Mov Disord, 2015, 30(8): 1068-1076

[8] PostumaRB, BergD, SternM, et al.. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord, 2015, 30(12): 1591-1601

[9] DemirkiranM, BozdemirH, SaricaY. Vascular parkinsonism:a distinct, heterogeneous clinical entity. Acta Neurol Scand, 2001, 104: 63-67

[10] BlazejewskaAI, SchwarzST, PitiotA, et al.. Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI. Neurology, 2013, 81: 534-540

[11] KimJM, JeongHJ, BaeYJ, et al.. Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Parkinsonism Relat Disord, 2016, 26: 47-54

[12] BaeYJ, KimJM, KimE, et al.. Loss of Nigral Hyperintensity on 3 Tesla MRI of Parkinsonism: Comparison With 123I-FP-CIT SPECT. Mov Disord, 2016, 31(5): 684-692

[13] WardWJ, ZuccaFA, DuynJH, et al.. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol, 2014, 13(10): 1045-1060

[14] TsaiFY, ShihYY, ChanWP, et al.. Practical aspects of shortening acquisition time in brain MR susceptibility-weighted imaging. Neuroradiol J, 2012, 25(6): 649-656

[15] GasparottiR, PinelliL, LiserreR. New MR sequences in daily practice: susceptibility weighted imaging. A pictorial essay. Insights Imaging, 2011, 2(3): 335-347

[16] MahlknechtP, HotterA, HusslA, et al.. Significance of MRI in diagnosis and differential diagnosis of Parkinson’s disease. Neurodegener Dis, 2010, 7(5): 300-318

[17] SeppiK, SchockeMF. An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism. Curr Opin Neurol, 2005, 18: 370-375

[18] GodauJ, HusslA, LolekhaP, et al.. Neuroimaging: current role in detecting pre-motor Parkinson’s disease. Mov Disord, 2012, 27(5): 634-643

[19] SchuffN. Potential role of high-field MRI for studies in Parkinson’s disease. Mov Disord, 2009, 24(Suppl2): S684-S690

[20] PéranP, CherubiniA, AssognaF, et al.. Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature. Brain, 2010, 133(11): 3423-3433

[21] GrögerA, BergD. Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson’s disease? Implications from MRI and TCS studies. J Neural Transm, 2012, 119(12): 1523-1528

[22] OhtsukaC, SasakiM, KonnoK, et al.. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat Disord, 2014, 20: 755-760

[23] HotterA, EsterhammerR, SchockeMF, et al.. Potential of advanced MR imaging techniques in the differential diagnosis of parkinsonism. Mov Disord, 2009, 4(Suppl2): S711-S720